Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Cancer Prevention and Control (CP) Program

If you would like to be added to the mailing list for the CP Program and receive meeting dates and times, please contact Dr. Jerod Stapleton and Dr. Krystle Kuhs.

The CP Research Program unites highly complementary strengths in the areas of population-based research and community-based cancer control research with the overarching goal of reducing cancer disparities in Kentucky with an emphasis on the state’s Appalachian and rural populations.

CP program strengths include studies focused on uncovering the role environmental exposures play in Kentucky’s high cancer incidence rates, trials of health behavior and cancer screening interventions that address unique cultural barriers, and intervention and policy research to reduce environmental risks for lung cancer.

The CP program has three thematic areas:

  1. Identification of social, cultural, behavioral, genetic and environmental factors that contribute to the elevated cancer incidence and mortality rates
  2. Design, testing, implementation and evaluation of intervention strategies that address identified risk factors (barriers) and reduce the cancer burden
  3. Development of population-based methods and measures that facilitate inter-programmatic cancer research directed at more precisely identifying the distribution of treatment patterns and biomarkers in the population.

CP research encompasses all segments of the cancer control continuum: prevention, early detection, treatment and survivorship.

  • Monthly Meetings

    The CP Program’s monthly meetings are designed to facilitate new research proposals and to encourage collaborations between CP members and the members of Markey’s other research programs. 

  • Interest Groups

    CP members are integral members of some of Markey’s most collaborative working groups, including the Breast Cancer Translational Group, the Lung Cancer Translational Group, and the cancer center’s Molecular Tumor Board.